Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.72
TRNX's Cash to Debt is ranked higher than
54% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. TRNX: 0.72 )
TRNX' s 10-Year Cash to Debt Range
Min: 0.18   Max: No Debt
Current: 0.72

Equity to Asset 0.74
TRNX's Equity to Asset is ranked higher than
77% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. TRNX: 0.74 )
TRNX' s 10-Year Equity to Asset Range
Min: 0.42   Max: 0.79
Current: 0.74

0.42
0.79
F-Score: 5
Z-Score: 3.30
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -7.74
TRNX's Operating margin (%) is ranked higher than
57% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. TRNX: -7.74 )
TRNX' s 10-Year Operating margin (%) Range
Min: -16.1   Max: -2.74
Current: -7.74

-16.1
-2.74
Net-margin (%) -11.71
TRNX's Net-margin (%) is ranked higher than
56% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. TRNX: -11.71 )
TRNX' s 10-Year Net-margin (%) Range
Min: -27.11   Max: -7.84
Current: -11.71

-27.11
-7.84
ROE (%) -6.93
TRNX's ROE (%) is ranked higher than
59% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. TRNX: -6.93 )
TRNX' s 10-Year ROE (%) Range
Min: -24.85   Max: -4.99
Current: -6.93

-24.85
-4.99
ROA (%) -5.16
TRNX's ROA (%) is ranked higher than
59% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. TRNX: -5.16 )
TRNX' s 10-Year ROA (%) Range
Min: -10.5   Max: -3.32
Current: -5.16

-10.5
-3.32
ROC (Joel Greenblatt) (%) -17.40
TRNX's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 13.69 vs. TRNX: -17.40 )
TRNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -20.92   Max: -5.5
Current: -17.4

-20.92
-5.5
Revenue Growth (%) -6.10
TRNX's Revenue Growth (%) is ranked higher than
56% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. TRNX: -6.10 )
TRNX' s 10-Year Revenue Growth (%) Range
Min: -6.1   Max: -2.7
Current: -6.1

-6.1
-2.7
EPS Growth (%) -17.80
TRNX's EPS Growth (%) is ranked higher than
64% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. TRNX: -17.80 )
TRNX' s 10-Year EPS Growth (%) Range
Min: -38.1   Max: -17.8
Current: -17.8

-38.1
-17.8
» TRNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

TRNX Guru Trades in Q2 2013

Steven Cohen 838,574 sh (+19.76%)
Paul Tudor Jones 475,000 sh (+18.75%)
» More
Q3 2013

TRNX Guru Trades in Q3 2013

Jim Simons 61,400 sh (New)
Paul Tudor Jones Sold Out
Steven Cohen 530,855 sh (-36.7%)
» More
Q4 2013

TRNX Guru Trades in Q4 2013

Steven Cohen Sold Out
Jim Simons Sold Out
» More
Q1 2014

TRNX Guru Trades in Q1 2014

Steven Cohen 176,057 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with TRNX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.00
TRNX's P/B is ranked higher than
81% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. TRNX: 2.00 )
TRNX' s 10-Year P/B Range
Min: 1.47   Max: 2.66
Current: 2

1.47
2.66
P/S 3.20
TRNX's P/S is ranked higher than
67% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. TRNX: 3.20 )
TRNX' s 10-Year P/S Range
Min: 2.22   Max: 3.91
Current: 3.2

2.22
3.91
EV-to-EBIT -43.51
TRNX's EV-to-EBIT is ranked lower than
52% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 44.62 vs. TRNX: -43.51 )
TRNX' s 10-Year EV-to-EBIT Range
Min: 641.6   Max: 1265.7
Current: -43.51

641.6
1265.7
Current Ratio 2.67
TRNX's Current Ratio is ranked higher than
68% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. TRNX: 2.67 )
TRNX' s 10-Year Current Ratio Range
Min: 2.19   Max: 3.29
Current: 2.67

2.19
3.29
Quick Ratio 1.61
TRNX's Quick Ratio is ranked higher than
63% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. TRNX: 1.61 )
TRNX' s 10-Year Quick Ratio Range
Min: 1.18   Max: 1.99
Current: 1.61

1.18
1.99

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.80
TRNX's Price/Tangible Book is ranked higher than
64% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 6.18 vs. TRNX: 6.80 )
TRNX' s 10-Year Price/Tangible Book Range
Min: 4.08   Max: 11.71
Current: 6.8

4.08
11.71
Price/Median PS Value 1.20
TRNX's Price/Median PS Value is ranked higher than
71% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. TRNX: 1.20 )
TRNX' s 10-Year Price/Median PS Value Range
Min: 0.86   Max: 1.36
Current: 1.2

0.86
1.36
Earnings Yield (Greenblatt) 0.30
TRNX's Earnings Yield (Greenblatt) is ranked lower than
60% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. TRNX: 0.30 )
TRNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 0.3
Current: 0.3

0.1
0.3

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:T98.Germany
Tornier N.V. focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.
» More Articles for NAS:TRNX

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Tornier Announces Second Quarter 2014 Conference Call Jul 10 2014
Tornier Announces Second Quarter 2014 Conference Call Jul 10 2014
Wright Medical And Tornier See A Desirable Partner Choose Another Jul 01 2014
TORNIER N.V. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 27 2014
Tornier NV Stock Upgraded (TRNX) Jun 06 2014
Stryker deal would be negative for Wright Medical, Tornier, says RBC Capital May 29 2014
TORNIER N.V. Financials May 14 2014
A Step In The Right Direction For Tornier May 08 2014
Tornier to Present at the Bank of America Merrill Lynch 2014 Health Care Conference May 08 2014
Tornier upgraded by Summer Street Research May 07 2014
Tornier upgraded to Neutral from Sell at Summer Street May 07 2014
Tornier N.V.'s (TRNX) CEO David Mowry on Q1 2014 Results - Earnings Call Transcript May 06 2014
Q1 2014 Tornier N V Earnings Conference Call (TRNX) Q1 2014 Results - Earnings Call Webcast May 06 2014
TORNIER N.V. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 06 2014
Tornier Reports First Quarter 2014 Results May 06 2014
Q1 2014 Tornier NV Earnings Release - After Market Close May 06 2014
Hedge Funds Like European Shipping Stocks As Market Recovers Mar 26 2014
A Wall Street Transcript Interview with Joanne K. Wuensch, a Research Analyst in the Cardiology,... Mar 24 2014
Tornier upgraded to Outperform from Market Perform at Wells Fargo Mar 20 2014
A Wall Street Transcript Interview with Matt Miksic, a Managing Director and Senior Research Analyst... Mar 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide